LATE-BREAKING CLINICAL TRIALS | CORONARY III

Sunday, March 8, 2026

3:30 PM - 4:35 PM EST

Location: International Ballroom Center

Moderator(s)

George Dangas, MD, MACC, MSCAI

PROFESSOR OF CARDIOLOGY
The Mount Sinai Hospital
New York, New York, United States

Disclosure(s): No financial relationships to disclose
Adnan Kastrati, MD

Senior Consultant, Head of Catheterization Laboratory
Deutsches Herzzentrum Muenchen
Munich, Bayern, Germany

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Tiziana Claudia Aranzulla, MD, MSc

Interventional cardiology
A.O. Ordine Mauriziano di Torino
Turin, Italy

Disclosure(s): No financial relationships to disclose
Abhishek Chaturvedi, MD

Interventional Cardiologist & Assistant Professor of Medicine
West Virginia University Heart & Vascular Institute, United States

Disclosure(s): No financial relationships to disclose
Michael J. Cowley, MD, MSCAI

Emeritus Professor of Medicine (Cardiology)
Virginia Commonwealth University Medical Center, Pauley Heart Center
Cary, North Carolina, United States

Disclosure(s): No financial relationships to disclose
Joost Daemen, MD, PhD

Interventional Cardiologist
Erasmus MC Thoraxcenter
Rotterdam, Zuid-Holland, Netherlands

Disclosure(s): Pulse Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medial Inc: Consulting Fees (e.g., advisory boards) (Ongoing)
Timothy D. Henry, MD

Director, The Carl and Edyth Lindner Center for Research and Education
The Christ Hospital
Bellevue, Kentucky, United States

Disclosure(s): No financial relationships to disclose
Michael J. Lipinski, MD, PhD

Interventional Cardiologist
Lee Health Heart Institute
Fort Myers, Florida, United States

Disclosure(s): Pfizer: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Sanofi/Genzyme: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); United Healthcare: Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Patrick W. Serruys, MD, PhD

Professor of Medical Intervention & Innovation
University of Galway, Ireland

Disclosure(s): Merillife Sciences: Consulting Fees (e.g., advisory boards) (Ongoing)
Christian Spaulding, MD, PhD

Professor of Cardiology
European Hospital Georges Pompidou, Paris, France
Paris, France

Disclosure(s): Abbott, Asahi, BD, Boston Scientific, Conavi, Cook, Cordis, Endovascular Engineering, Evident Vascular, Gore, InfraRedx, Medtronic, Penumbra, Philips, RapidAI, Rampart IC, R3, Regeneron, Shockwave, Siemens, SoniVie, Teleflex, Terumo, Thrombolex, Vent: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scietific: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025); CERC: Grant/Research Support (Ongoing); Cordis, Endovascular Division: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Consulting Fees (e.g., advisory boards) (Terminated, June 30, 2025); French Ministry of Health: Grant/Research Support (Terminated, January 2, 2025); MedAlliance: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, July 30, 2025); Techwald: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Valcare Medical: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025)
Olga Toleva, MD, MPH

Lead of Advanced Coronary Physiology Program
Georgia Heart Institute
Gainesville, Georgia, United States

Disclosure(s): Philips; Abbott: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Disclosure(s):

George Dangas, MD, MACC, MSCAI: No financial relationships to disclose

Adnan Kastrati, MD: No financial relationships to disclose

Tiziana Claudia Aranzulla, MD, MSc: No financial relationships to disclose

Abhishek Chaturvedi, MD: No financial relationships to disclose

Michael J. Cowley, MD, MSCAI: No financial relationships to disclose

Joost Daemen, MD, PhD: Pulse Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medial Inc: Consulting Fees (e.g., advisory boards) (Ongoing)

Timothy D. Henry, MD: No financial relationships to disclose

Michael J. Lipinski, MD, PhD: Pfizer: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Sanofi/Genzyme: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); United Healthcare: Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Patrick W. Serruys, MD, PhD: Merillife Sciences: Consulting Fees (e.g., advisory boards) (Ongoing)

Christian Spaulding, MD, PhD: Abbott, Asahi, BD, Boston Scientific, Conavi, Cook, Cordis, Endovascular Engineering, Evident Vascular, Gore, InfraRedx, Medtronic, Penumbra, Philips, RapidAI, Rampart IC, R3, Regeneron, Shockwave, Siemens, SoniVie, Teleflex, Terumo, Thrombolex, Vent: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scietific: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025); CERC: Grant/Research Support (Ongoing); Cordis, Endovascular Division: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Consulting Fees (e.g., advisory boards) (Terminated, June 30, 2025); French Ministry of Health: Grant/Research Support (Terminated, January 2, 2025); MedAlliance: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, July 30, 2025); Techwald: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Valcare Medical: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025)

Olga Toleva, MD, MPH: Philips; Abbott: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)